Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences.
作者信息
Kim In-Ho, Choi Wonyoung, Han Hye Sook
机构信息
Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Center for Clinical Trials, National Cancer Center, Goyang, Korea.
出版信息
J Gastric Cancer. 2024 Oct;24(4):353-355. doi: 10.5230/jgc.2024.24.e40.
Abstract
摘要
相似文献
1
Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences.回复：关于《指导的必要性：通过证据、临床判断和患者偏好的相互作用优化II/III期微卫星高度不稳定胃癌的辅助治疗》的评论
J Gastric Cancer. 2024 Oct;24(4):353-355. doi: 10.5230/jgc.2024.24.e40.
2
The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences.指导的必要性：通过证据、临床判断和患者偏好的相互作用优化II/III期微卫星高度不稳定胃癌的辅助治疗
J Gastric Cancer. 2024 Jul;24(3):243-245. doi: 10.5230/jgc.2024.24.e26.
3
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.微卫星高度不稳定型胃癌的辅助化疗
Cancer Res Treat. 2020 Oct;52(4):1178-1187. doi: 10.4143/crt.2020.313. Epub 2020 Jun 11.
4
The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses.微卫星不稳定性对 II 期和 III 期胃癌化疗的获益减弱：一项大型队列研究的结果及亚组分析。
Int J Cancer. 2015 Aug 15;137(4):819-25. doi: 10.1002/ijc.29449. Epub 2015 Feb 26.
5
Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial.单患者分类分析、微卫星不稳定性和爱泼斯坦-巴尔病毒状态预测II/III期胃癌的临床结局：CLASSIC试验结果
Yonsei Med J. 2019 Feb;60(2):132-139. doi: 10.3349/ymj.2019.60.2.132.
6
A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.一项关于可切除胃癌复发后微卫星不稳定性或错配修复状态预后意义的多队列研究
Cancer Res Treat. 2020 Oct;52(4):1153-1161. doi: 10.4143/crt.2020.173. Epub 2020 May 4.
7
Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study.微卫星不稳定性与辅助治疗在 pT1N1 胃癌中的疗效：一项多队列研究。
Ann Surg Oncol. 2021 Dec;28(13):8908-8915. doi: 10.1245/s10434-021-10084-0. Epub 2021 Aug 16.
8
Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection.散发性胃癌中的微卫星不稳定性：其预后作用及对 R0 切除术后基于 5-FU 的化疗的指导意义。
Int J Cancer. 2012 Jul 15;131(2):505-11. doi: 10.1002/ijc.26399. Epub 2011 Nov 19.
9
Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.错配修复缺陷或微卫星不稳定型胃癌患者的辅助化疗：系统评价和荟萃分析。
Ann Surg Oncol. 2022 Apr;29(4):2324-2331. doi: 10.1245/s10434-021-11050-6. Epub 2021 Nov 18.
10
Survival impact of microsatellite instability in stage II gastric cancer patients who received S-1 adjuvant monotherapy after curative resection.根治性切除术后接受 S-1 辅助单药治疗的 II 期胃癌患者中微卫星不稳定性的生存影响。
Sci Rep. 2023 Jul 4;13(1):10826. doi: 10.1038/s41598-023-37870-y.
引用本文的文献
1
The Current Evidence and Future Direction of Adjuvant Treatment for Gastric Cancer in the Era of Precision Medicine.精准医学时代胃癌辅助治疗的当前证据与未来方向
Cancer Res Treat. 2025 Jul;57(3):621-634. doi: 10.4143/crt.2024.1222. Epub 2025 Jan 23.
本文引用的文献
1
The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences.指导的必要性：通过证据、临床判断和患者偏好的相互作用优化II/III期微卫星高度不稳定胃癌的辅助治疗
J Gastric Cancer. 2024 Jul;24(3):243-245. doi: 10.5230/jgc.2024.24.e26.
2
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.辅助纳武利尤单抗联合化疗对比安慰剂联合化疗用于 D2 或更广泛淋巴结清扫术后的 III 期胃癌或胃食管结合部癌（ATTRACTION-5）：一项随机、多中心、双盲、安慰剂对照的 III 期临床试验。
Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. doi: 10.1016/S2468-1253(24)00156-0. Epub 2024 Jun 18.
3
Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis.微卫星高度不稳定早期胃癌的辅助化疗和新辅助化疗：一项系统评价与荟萃分析
Ther Adv Med Oncol. 2024 Feb 29;16:17588359241231259. doi: 10.1177/17588359241231259. eCollection 2024.
4
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.中国临床肿瘤学会（CSCO）：胃癌诊断与治疗临床实践指南，2023 年版。
Cancer Commun (Lond). 2024 Jan;44(1):127-172. doi: 10.1002/cac2.12516. Epub 2023 Dec 31.
5
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.新辅助和辅助帕博利珠单抗联合化疗治疗局部晚期胃或胃食管交界癌（KEYNOTE-585）：多中心、双盲、随机 3 期研究的中期分析。
Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19.
6
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.可切除食管胃结合部腺癌患者围手术期使用阿替利珠单抗联合氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛治疗的随机、多中心、Ⅱ/Ⅲ期 DANTE/IKF-s633 试验的中期结果。
J Clin Oncol. 2024 Feb 1;42(4):410-420. doi: 10.1200/JCO.23.00975. Epub 2023 Nov 14.
7
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach.《2022年韩国胃癌诊疗指南：基于证据的多学科方法》
J Gastric Cancer. 2023 Jan;23(1):3-106. doi: 10.5230/jgc.2023.23.e11.
8
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.新辅助纳武利尤单抗联合伊匹单抗和辅助纳武利尤单抗治疗局部缺陷错配修复/微卫星不稳定高型胃或胃食管结合部腺癌：GERCOR NEONIPIGA Ⅱ期研究。
J Clin Oncol. 2023 Jan 10;41(2):255-265. doi: 10.1200/JCO.22.00686. Epub 2022 Aug 15.
9
Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.错配修复缺陷或微卫星不稳定型胃癌患者的辅助化疗：系统评价和荟萃分析。
Ann Surg Oncol. 2022 Apr;29(4):2324-2331. doi: 10.1245/s10434-021-11050-6. Epub 2021 Nov 18.
10
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.微卫星高度不稳定型胃癌的辅助化疗
Cancer Res Treat. 2020 Oct;52(4):1178-1187. doi: 10.4143/crt.2020.313. Epub 2020 Jun 11.
Zotero 插件